Vaxart Inc Stock Price, News & Analysis

SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) announced presentations by Dr. Sean Tucker and Dr. James F. Cummings at the World Vaccine Congress Washington 2023 on April 5 and 6, 2023. Dr. Tucker will discuss advancements in oral tablet vaccinations aimed at blocking transmission and enhancing existing vaccines on April 5 at 4:40 p.m. ET. Dr. Cummings will present findings on Vaxart’s oral bivalent norovirus vaccine candidate on April 6 at 12:15 p.m. ET. Vaxart is a clinical-stage biotechnology company focusing on oral recombinant vaccines that do not require refrigeration.

Vaxart, Inc. (NASDAQ: VXRT) will host a key opinion leader (KOL) video webcast on March 28, 2023, at 1:00 p.m. ET, focusing on the health and economic impact of norovirus. The webcast will feature experts Jan Vinjé, Ph.D. from the CDC, and Sarah Bartsch from CUNY. Vaxart's management will discuss their investigational oral pill vaccine for norovirus, detailing two Phase 2 clinical trials. One study aims to assess the efficacy of a GI.1 vaccine candidate, with topline data expected in Q3 2023. Another trial will evaluate vaccine dosing for a possible Phase 3 study, with topline data due mid-2023.

Vaxart (NASDAQ: VXRT) has announced a strategic shift prioritizing its bivalent norovirus vaccine candidate following encouraging clinical trial results. The company has completed six trials demonstrating robust immunogenicity and safety in young adults and the elderly. Vaxart plans to report topline data from ongoing Phase 2 studies in mid-2023 and Q3 2023, respectively. The company ended 2022 with $95.7 million in cash but reported a net loss of $107.8 million, up from $70.5 million in 2021. Vaxart's research and development expenses surged to $81.1 million due to increased headcount and clinical trial costs, while revenue fell to $0.1 million from $0.9 million in 2021.

Vaxart, Inc. (NASDAQ: VXRT) will provide a business update and financial results for the year ending December 31, 2022, on March 15, 2023, after market close. A conference call with senior management is scheduled for the same day at 4:30 p.m. ET. Vaxart focuses on developing oral recombinant vaccines through a unique delivery system aimed at eliminating needle-stick injuries. Their product pipeline includes vaccines for coronavirus, norovirus, seasonal influenza, RSV, and HPV, along with existing intellectual property protections.

Vaxart, Inc. (NASDAQ: VXRT) announced the dosing of the first subject in its Phase 2 clinical trial for an oral bivalent norovirus vaccine on February 14, 2023. This trial aims to establish optimal vaccine dosing ahead of a possible Phase 3 trial. The vaccine demonstrated robust immunogenicity in Phase 1b, with IgA responses of 78% and 93% for GI.1 and GII.4 strains, respectively. Approximately 135 healthy adults will participate, analyzing safety and immunogenicity. The global norovirus market is estimated at over $10 billion, with significant annual health impacts in the U.S. Vaxart expects to report topline data in mid-2023.

Vaxart, Inc. (NASDAQ: VXRT) has appointed Phillip Lee as its new Chief Financial Officer, effective immediately. Lee brings nearly 15 years of experience in corporate finance, M&A, and advisory roles, having facilitated over $20 billion in transactions and raised over $1 billion in capital. CEO Andrei Floroiu expressed excitement about Lee's contribution to Vaxart's mission of combating infectious diseases through its oral vaccine platform. Vaxart focuses on developing innovative oral vaccines for various diseases, including COVID-19 and HPV, leveraging its proprietary delivery technology.

Vaxart, Inc. (Nasdaq: VXRT) announced a new study funded by the Bill & Melinda Gates Foundation to assess an oral norovirus vaccine aimed at protecting breastfeeding mothers and their infants. The study will investigate whether the vaccine induces antibodies in breast milk and transfers them to infants. Norovirus sickens approximately 21 million people in the U.S. annually, posing significant health risks, especially to children under five. The research aligns with Vaxart’s commitment to global access for low- and middle-income countries if the vaccine is effective.